Salazopyrin EN in rheumatoid arthritis
A meeting on the effects of Salazopyrin EN in rheumatoid arthritis was held at St Thomas's Hospital on 11 December 1986. Dr I Bjarnason (Northwick Park Hospital) presented evidence to suggest that non-steroidal antiinflammatory drugs (NSAIDs) increase intestinal permeability through a mechanism of reduced mucosal prostaglandin production. Salazopyrin (SASP) was found to reduce drastically the NSAID induced small intestinal inflammation, whereas other second line drugs did not. The beneficial effect of SASP on the joints themselves thus appeared to be independent of the intestinal action of the drug. This suggested that previous speculation about the importance of the intestine in the aetiology of rheumatoid arthritis (RA) was incorrect.
Dr J R Hoult (King's College, London) discussed the pharmacological actions of SASP. He pointed out that there were many unanswered questions concerning diseases in which SASP was used, which hampered analysis of the mode of action. In particular, the unknown aetiology of ulcerative colitis and RA, the lack of simple models of the diseases, and the fact that SASP was a unique drug whose target cell(s) or molecule(s) were unknown and which had two potential active moietiessulphapyridine and S-aminosalicylic acid. 
